|
|
Volumn 88, Issue 12, 1996, Pages 788-789
|
|
Topotecan: After FDA and ASCO, what's next?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
PACLITAXEL;
TOPOTECAN;
ADVANCED CANCER;
ANTINEOPLASTIC ACTIVITY;
CANCER CHEMOTHERAPY;
DRUG MARKETING;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
NOTE;
OVARY CANCER;
RECURRENT CANCER;
ANTINEOPLASTIC AGENTS;
CAMPTOTHECIN;
FEMALE;
GENITAL NEOPLASMS, FEMALE;
HUMANS;
RECURRENCE;
TOPOTECAN;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 0029952607
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/88.12.788 Document Type: Note |
|
Times cited : (10)
|
|
References (0)
|